LIVE POLIO IRUS VACCINES

More documents

Recommendations

Info

imimmmmmñimmimmm-ñmñmñrmimmimmmmmñmmmm FIRST SESSION MONDAY, 6 JUNE 1960, 9:30 a.m. mnmiimimrmnmiiiiiii,,iiiimiiliniimiiii Chairman DR. GAYLORD W. ANDERSON Director, School of Public Health University of Minnesota Minneapolis, Minnesota INTRODUCTORY REMARKS Dr. Abraham Horwitz, Director Pan American Sanitary Bureau Regional Office, World Health Organization Washington, D. C. Dr. Raymond D. Ritts Department of Microbiology Georgetown University Washington, D. C. TOPIC I. GENERAL CONSIDERATIONS Presentation of Paper by: Dr. Hilary Koprowski TOPIC II. SAFETY. (A) LABORATORY EVIDENCE OF ATTENUA TION AND SAFETY Presentation of Papers by: Dr. Joseph L. Melnick (DISCUSSION) Dr. Victor J. Cabasso (DISCUSSION) Dr. Horace L. Hodes (DISCUSSION) 1
Page 1 and 2: LIVE POLIO IRUS VACCINES Papers Pre
Page 3 and 4: SECOND INTERNATIONAL CONFERENCE ON
Page 5: Preface The accumulation of informa
Page 8 and 9: Page Discussion .......... .......
Page 10 and 11: Page 6. Vaccination of Full-Term In
Page 12 and 13: Page 23. Vaccination against Poliom
Page 14 and 15: Dr. Ghislain COURTOIS Director, Pri
Page 16 and 17: Dr. Edith PETTE Institute for the R
Page 20 and 21: mi INTRODUCTORY REMARKS DR. ABRAHAM
Page 22 and 23: ñmmmmrmmmrmmiiii~~~~mmIIi~~;mñmii
Page 24 and 25: Tin Anniversary of Live Poliovirus
Page 26 and 27: Tin Anniversary of Live Poliovirus
Page 28 and 29: _____ Tin Anniversary of Live Polio
Page 30 and 31: Problems with Live Poliovirus Vacci
Page 34 and 35: ______ Problems with Live Polioviru
Page 46 and 47: Discussion 29 Discussion 29 Now he
Page 48 and 49: 2. ASSESSMENT OF CORRELATION BETWEE
Page 50 and 51: Correlation of In Vitro Markers and
Page 56 and 57: DISCUSSION CHAIRMAN ANDERSON: These
Page 58 and 59: 3. A PHYSICAL PROPERTY AS A VIRUS M
Page 60 and 61: A Physical Property as a Virus Mark
Page 62 and 63: DR. ÉOBBINS: In the course of our
Page 64 and 65: Discussion 47 ble, by introduction
Page 66 and 67: Discussion 49 belonging to one gene
Page 68:
TníTmmnTmmTITTrmlrmnrm SECOND SESS
Page 71 and 72:
54 Safety-Laboratory Evidence of At
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
DISCUSSION CHAIRMAN BURNET: The pap
Page 85 and 86:
5. EXPERIMENTAL STUDIES ON ANIMALS
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
DISCUSSION CHAIRMAN BURNET: The pap
Page 105 and 106:
88 88 Discussion Discussion~~~~~~~~
Page 107 and 108:
7. LABORATORY INVESTIGATIONS OF THR
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
DISCUSSION CHAIRMAN BURNET: Thank y
Page 117 and 118:
100 Discussion in his hands and we
Page 119 and 120:
102 Safety-Laboratory Evidence of A
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
110 Discussion said that the real p
Page 130 and 131:
nTIITTrTTrmTmmrmTm TOPIC II. SAFETY
Page 132 and 133:
Effectiveness of Trivalent Vaccine
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
DISCUSSION CHAIRMAN ZHDANOV: Thank
Page 140 and 141:
who had no antibody at all, as demo
Page 142 and 143:
Laboratory Investigations of Attenu
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
DR. BARON: When we come to the prob
Page 152 and 153:
Epidemiological, Virological Survey
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
DISCUSSION CHAIRMAN ZHDANOV: This p
Page 162 and 163:
Spread of Vaccine Strain of Poliovi
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Discussion 157 Discussion 157 One o
Page 176 and 177:
Discussion 159 Discussion 159 ence
Page 178 and 179:
13. MINNESOTA STUDIES WITH ORAL POL
Page 180 and 181:
Minnesota Studies With Oral Poliomy
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Capacity of Live Attenuated Poliovi
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202:
I TTmTIIITITIT?~~~~~~~~~~T~~~TTTT~~
Page 205 and 206:
188 Safety-Field Evidence of Safety
Page 207 and 208:
190 Safety-F'ield Evidence of Safet
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
vaccine combined in a mixture conta
Page 217 and 218:
Page 219 and 220:
DISCUSSION CHAIRMAN GEAR: Thank you
Page 221 and 222:
. _ 204 Discussion I__ _ 1 CC w 4CC
Page 223 and 224:
206 206 Discussion Discussion We kn
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
216 216 Safety-Field Evidence of Sa
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
224 Saf etv-Field Evidence of Saf e
Page 243 and 244:
The authors wish to express their a
Page 245 and 246:
IIIIIII1I1)1III1II111111:l lrmillll
Page 247 and 248:
- 230 Efficacy-Laboratory Evidence
Page 249 and 250:
232 Efficacv-Laboratory Evidence l2
Page 251 and 252:
234 Efficacy-Laboratory Evidence 40
Page 253 and 254:
236 Efflcacy-Laboratory Evidence 23
Page 255 and 256:
Page 257 and 258:
2. VIROLOGIC AND SEROLOGIC INVESTIG
Page 259 and 260:
242 Efficacy-Laboratory Evidence ca
Page 261 and 262:
244 Efficacy-Laboratory Evidence Z
Page 263 and 264:
246 Efficacy-Laboratory Evidence TA
Page 265 and 266:
Page 267 and 268:
250 Efficacy-Laboratory Evidence LO
Page 269 and 270:
Page 271 and 272:
254 TABLE 21. Efficacy-Laboratory E
Page 273 and 274:
256 Efficacy-Laboratory Evidence QC
Page 275 and 276:
258 Efficacy-Laboratory Evidence Is
Page 277 and 278:
260 Efficacy-Laboratory Evidence o
Page 279 and 280:
Page 281 and 282:
264 Effcaey-Laboratory Evidence 264
Page 283 and 284:
DISCUSSION CHAIRMAN GEAR: The last
Page 285 and 286:
268 Discussion " I10,00 1-- , 2,000
Page 287 and 288:
3. VIROLOGICAL FINDINGS AND ANTIBOD
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
278 Efficacy-Laboratory Evidence sq
Page 297 and 298:
280 Efficacy-Laboratory Evidence Po
Page 299 and 300:
282 Efficacy-Laboratory Evidence to
Page 302:
_____~~~~~~~~~~~~~~~~~~~~~~ FIFTH S
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
6. VACCINATION OF FULL-TERM INFANTS
Page 313 and 314:
296 296 Efficacy-Laboratory Evidenc
Page 315 and 316:
Page 317 and 318:
300 Efflcacy-Laboratory Evidence TA
Page 319 and 320:
7. THE RESPONSE OF NEWBORN INFANTS
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
8. PRELIMINARY REPORT ON THE SUSCEP
Page 327 and 328:
310 310 Efficaey-Laboratory Evidenc
Page 329 and 330:
312 Efficacy-Laboratory Evidence ch
Page 331 and 332:
314 314 Efficacy-Laboratory Evidenc
Page 333 and 334:
Page 335 and 336:
318 TABLE 3. Efficacy-Laboratory Ev
Page 337 and 338:
320 Efficacy-Laboratory Evidence (u
Page 339 and 340:
DISCUSSION CHAIRMAN HILLEBOE: Befor
Page 341 and 342:
324 Discussion INFLUENCES OF ANTIBO
Page 343 and 344:
326 Discussion 326 Discussion Would
Page 345 and 346:
328 Discussion if we give the Black
Page 347 and 348:
10. RECENT EXPERIENCE WITH THE LEDE
Page 349 and 350:
332 Efficacy-Laboratory Evidence O/
Page 351 and 352:
Page 353 and 354:
336 Efficacy-Laboratory Evidence pr
Page 355 and 356:
338 Efficacy--Laboratory Evidence G
Page 357 and 358:
340 Efficacy-Laboratory Evidence CD
Page 359 and 360:
Page 361 and 362:
344 Efficacy-Laboratory Evidence ti
Page 363 and 364:
i . ;; ,---- , , _ ·, ,,, ,, 346 E
Page 365 and 366:
348 Efficacy-Laboratory Evidence ta
Page 367 and 368:
Page 369 and 370:
352 Efficacy-Laboratory Evidence mo
Page 372:
ITnTTITTTIIrmrTTTmTTmTmm - niiii ii
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
368 Efflcacy-Laboratory Evídence 3
Page 387 and 388:
370 Efficacy-Laboratory Evidence RE
Page 389 and 390:
372 372 Discussion Discussion~~~~~~
Page 391 and 392:
374 Discussion 374 Discussion~~~~~
Page 393 and 394:
376 Discussion 376 Discussion~~~~~~
Page 395 and 396:
Page 397 and 398:
Page 399 and 400:
Page 401 and 402:
384 Effieacy-Laboratory Evidence 38
Page 403 and 404:
15. USE OF SABIN'S LIVE POLIOVIRUS
Page 405 and 406:
388 Efficacy-Laboratory Evidence o
Page 407 and 408:
Page 409 and 410:
_ 392 Efficacy-Laboratory Evidence
Page 411 and 412:
Page 413 and 414:
Page 415 and 416:
Page 417 and 418:
Page 419 and 420:
402 Efficacy-Laboratory Evidence z
Page 421 and 422:
404 Efficacy-Laboratory Evidence )
Page 423 and 424:
406 Efficacy-Laboratory Evidence c
Page 425 and 426:
408 Efficacy-Laboratory Evidence l)
Page 427 and 428:
DISCUSSION CHAIRMAN LÉPINE: The pa
Page 429 and 430:
412 Discussion tion. I do not see h
Page 431 and 432:
414 Efficacy-Field Evidence ference
Page 433 and 434:
416 Effcacy-Field Evidence TABLE 3.
Page 435 and 436:
418 Efficacy-Field Evidence DAYS OF
Page 437 and 438:
preparation. Large-scale field tria
Page 439 and 440:
422 Efficacy-Field Evidence taneous
Page 441 and 442:
424 Efficacy-Field Evidence TABLE 1
Page 443 and 444:
426 Efficacy-Field Evidence 2048 ,a
Page 445 and 446:
428 Efficacy-Field Evidence 60o S0
Page 447 and 448:
430 Discussion 430 Discussion~~~~~~
Page 449 and 450:
432 Discussion tioned already in th
Page 452 and 453:
lilllmlllllll'll1lllllilrrmllllllll
Page 454 and 455:
Large-Scale Field Trial with Oral C
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
18. PRELIMINARY REPORT OF EPIDEMIOL
Page 464 and 465:
Epidemiological Surveillance in Mas
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
DISCUSSION CHAIRMAN RHODES: These t
Page 476 and 477:
Discussion 459 -~~~~Dsuso 5 We did
Page 478 and 479:
Discussion 461 logical anomalies of
Page 480 and 481:
Discussion 463 The majority of chil
Page 482:
case of poliomyelitis, if it was po
Page 485 and 486:
Page 487 and 488:
470 Efficacy-Field Evidence 470 Eff
Page 489 and 490:
Page 491 and 492:
20. LIVE VIRUS VACCINE STUDIES IN S
Page 493 and 494:
Page 495 and 496:
Page 497 and 498:
DISCUSSION CHAIRMAN RHODES: These t
Page 499 and 500:
21. MATERIAL ON THE IMMUNOLOGICAL A
Page 501 and 502:
484 Efficacy-Field Evidence 484 Efi
Page 503 and 504:
486 Efficacy-Field Evidence 486 iEf
Page 505 and 506:
488 Efficacy-Field Evidence - TABLE
Page 507 and 508:
Page 509 and 510:
Page 511 and 512:
494 Efficaey-Field Evidence TABLE 9
Page 513 and 514:
496 Efficaey-Field Evidence TABLE 1
Page 515 and 516:
498 Efficacy-Field Evidence Qo - Co
Page 517 and 518:
500 Etfficacy-Field Evidence 500 Ef
Page 520:
lmllliiimlll1llrrmmIiiiiiiiiiiiiii,
Page 523 and 524:
506 Discussi on hausted the morbidi
Page 525 and 526:
Page 527 and 528:
510 Efficacy-Field Evidence b 'r3 `
Page 529 and 530:
512 ol o c,- 4 3- 0 7 Efficacy-Fiel
Page 531 and 532:
514 Efficacy-Field Evidence b, U *
Page 533 and 534:
516 Efficacy-Field Evidence o e 0 1
Page 535 and 536:
518 Efficacy-Field Evidence in the
Page 537 and 538:
520 Efficacy-Field Evidence thing w
Page 539 and 540:
23. VACCINATION AGAINST POLIOMYELIT
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
528 Efficacy-Field Evidence MAP 2.
Page 547 and 548:
Page 549 and 550:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 551 and 552:
534 Efficacy-Field Evidence a still
Page 553 and 554:
536 Efficacy-Field Evidence frigera
Page 555 and 556:
538 TABLE 3. Efficacy-Field Evidenc
Page 557 and 558:
540 Efficacy-Field Evidence sented
Page 559 and 560:
Page 561 and 562:
544 Efficacy-Field Evidence Antibod
Page 563 and 564:
546 Efficacy-Field Evidence 250t 20
Page 565 and 566:
Page 567 and 568:
550 Efficacy-Field Evidence FIGURE
Page 569 and 570:
552 Efficacy-Field Evidence u o o
Page 571 and 572:
-Y 554 Efficacy-Field Evidence TABL
Page 573 and 574:
556 -- Efficacy-Field Evidence 0
Page 575 and 576:
c 558 Efficacy-Field Evidence o z o
Page 577 and 578:
560 Efficacy-Field Evidence Clayton
Page 579 and 580:
562 Efficacy-Field Evidence 2. Triv
Page 581 and 582:
564 Efficacy-Field Evidence and by
Page 583 and 584:
566 Efficacy-Field Evidence establi
Page 585 and 586:
568 Efficacy-Field Evidence Costa R
Page 587 and 588:
570 Efficacy-Fi eld Evidence Two su
Page 589 and 590:
572 Efficacy-Field Evidence o0 u p
Page 591 and 592:
DISCUSSION CHAIRMAN STUART-HARRIS:
Page 593 and 594:
27. LARGE-SCALE PRACTICAL TRIALS AN
Page 595 and 596:
578 Efficacy-Field Evidence some of
Page 597 and 598:
580 Efficacy-Field Evidence vaccine
Page 599 and 600:
582 Efficacy-Field Evidence more th
Page 601 and 602:
584 Efficacy-Field Evidence medical
Page 603 and 604:
586 Efficacy-Field Evidence immuniz
Page 605 and 606:
588 Efficacy-Field Evidence nationa
Page 608 and 609:
DISCUSSION CHAIRMAN VARGAS-MÉNDEZ:
Page 610 and 611:
Discussion 593 -~~~~~isuso 9 a stoo
Page 612 and 613:
Discussion 595 If the chain of tran
Page 614 and 615:
dence of immunization within a few
Page 616 and 617:
Discussion 599 the people in a few
Page 618 and 619:
Summary of the Conference 601 prese
Page 620:
The occurrence of poliomyelitis in
Page 624 and 625:
INDEX Abad Gómez, Héctor, 369 Abo
Page 626 and 627:
Index 609 Attack rates-continued hi
Page 628 and 629:
Index 611 Chromatography purificati
Page 630 and 631:
Index 613 Dosage-continued statisti
Page 632 and 633:
Index 615 Field trials-continued Le
Page 634 and 635:
Index 617 Human tissue-culture syst
Page 636 and 637:
Index 619 Intestinal tract-continue
Page 638 and 639:
Index 621 Markush, R. E., paper 435
Page 640 and 641:
Index 623 Newborns-continued degree
Page 642 and 643:
Index 625 Poliomyelitis, paralytic-
Page 644 and 645:
Index 627 Reversion dangers of, 485
Page 646 and 647:
Index 629 Spread-continued in the c
Page 648 and 649:
Index 631 Vaccination-continued rep
Page 650 and 651:
Index 633 Vaccine, Attenuated, Triv
show all

LIVE POLIO IRUS VACCINES

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?